The safety and effectiveness of 0.16 mg bevacizumab plus or minus additional laser photocoagulation in the treatment of retinopathy of prematurity

PURPOSE: Retinopathy of prematurity (ROP) is the leading cause of preventable blindness in premature infants. Antivascular endothelial growth factor (anti-VEGF) therapy has been used increasingly in treatment as a pharmacological alternative to laser therapy. In this study, we evaluate the results o...

Descripción completa

Detalles Bibliográficos
Autores principales: Akdogan, Muberra, Cevik, Sadik Gorkem, Sahin, Ozlem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552615/
https://www.ncbi.nlm.nih.gov/pubmed/31124508
http://dx.doi.org/10.4103/ijo.IJO_2115_18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552615/
https://www.ncbi.nlm.nih.gov/pubmed/31124508
http://dx.doi.org/10.4103/ijo.IJO_2115_18

Ejemplares similares